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Nucleoside transporters (NTs) play critical biological roles in humans, and to understand
the molecular mechanism of nucleoside transport requires high-resolution structural
information. However, the main bottleneck for structural analysis of NTs is the production
of pure, stable, and high quality native protein for crystallization trials. Here we report
a novel membrane protein expression and purification strategy, including construction
of a high-yield membrane protein expression vector, and a new and fast purification
protocol for NTs. The advantages of this strategy are the improved time efficiency, leading
to high quality, active, stable membrane proteins, and the efficient use of reagents and
consumables. Our strategymight serve as a useful point of reference for investigating NTs
and other membrane proteins by clarifying the technical points of vector construction and
improvements of membrane protein expression and purification.
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INTRODUCTION
Membrane proteins represent 20–30% of all genes in most sequenced genomes (Krogh et al., 2001)
and are targets for about half of all modern therapeutic drugs (Krogh et al., 2001; Bayley, 2009;
Andreeva et al., 2014). Membrane proteins, such as membrane transporters, receptors, enzymes,
and cell adhesion molecules, have been studied for decades on account of their critical biochemical
roles in the maintenance of vital cellular functions (Bowie, 2005; Von Heijne, 2006; Almén et al.,
2009; Anson, 2009). However, production of native membrane proteins has always proven to be a
bottleneck in structural and functional studies (Lacapere et al., 2007; Midgett and Madden, 2007).
Current production methods generally lead to a low yield of expression or result in overexpression
of misfolded protein (Drew et al., 2008).
Our particular interest is in nucleoside transporters (NTs). Their study is biologically and
clinically relevant because they are important in the uptake of nucleoside drug analogs.
Furthermore, nucleosides, adenosine in particular, regulate many aspects of heart, brain, and
immune system physiology (Johnson et al., 2012; Young et al., 2013; Rehan and Jaakola, 2015)
and so have great potential for therapeutic applications in cardiovascular disease, inflammation,
and cancer (Carrier et al., 2006; Hsu et al., 2012; Young et al., 2013; Valdés et al., 2014). However,
the molecular basis of the functional mechanisms of nucleoside transport remain poorly defined.
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One of the main reasons lies in the difficulty of production and
purification of recombinant NTs.
A standard approach for membrane protein production is
the expression of the target membrane protein as a fusion
protein, which can increase the stability and expression level of
the target (Alexandrov et al., 2001; Heijbel et al., 2009) and/or
makes it easier to follow the expression and purification (Drew
et al., 2005). A diverse range of soluble proteins have been used
as fusion partners including maltose binding protein (MBP),
thioredoxin, green fluorescence protein (GFP), and glutathione
S-transferase (GST) (Heijbel et al., 2009; Sammons and Gross,
2013; Gosch et al., 2014; Nguyen et al., 2014; Satoh et al., 2015).
MBP is one of the most commonly used for the generation of
fusion protein with membrane proteins in microbial expression
systems (Lorenzo et al., 1997; Dälken et al., 2010; Xu et al.,
2014). Because it is known to be well expressed and stable
in the Escherichia coli periplasm, MBP is generally used as an
N-terminal fusion of membrane proteins to be purified (Hu
et al., 2011), but is not used as a purification tag because of
the maltoside detergents used in solubilisation interfere. The
inconvenience of using a His-tag directly as an N-terminal fusion
of a membrane protein exposing its N-terminus in the periplasm
is that the presence of the His8 positive tag can alter the protein
topology (Von Heijne, 2006). To avoid this problem, we have
used MBP as a linker between the purification tag (8xHis) and
the membrane protein of interest, hence keeping the topological
stability of the target as well as the flexibility of His-tag
purification procedures (Ma et al., 2015). In addition, a specific
proteolytic cleavage site is added between the MBP and the target
protein. Classical approaches use proteases in solution together
with the protein so, after cleavage, an additional step is needed
to repurify the target protein from the protease and the cut tag.
The approach we have undertaken in this study is to combine
the use of a His tagged protease added directly onto the protein
bound to the purification column. As a result, the target protein is
specifically released into the flowthrough while the His-protease
and the His-MBP are retained on the IMAC (immobilized metal-
affinity chromatography) column, hence avoiding another round
of purification. We have used NupC (Escherichia coli, Uniprot
accession no.: P0AFF2) as a model protein to demonstrate the
efficiency of this approach, while additionally optimizing and
simplifying each prior purification step to decrease purification
time. This optimized purification procedure has been successfully
applied to other NTs (SI-Figure 1). In addition, we developed
an improved expression system by changing the promoter and
the linker described in our earlier study (Ma et al., 2015).
Compared to our previous approach, the optimized method is
faster and more cost effective. Similar optimization approaches
can be generally applied to the production of other membrane
proteins.
Abbreviations: C12E8, octaethylene glycol monododecyl ether; DDM, dodecyl-
β-D-maltoside; DM, decyl-β-D-maltoside; GFP, green fluorescence protein; GST,
glutathione S-transferase; IMAC, immobilized metal-affinity chromatography;
IPTG, isopropyl β-D-1-thiogalactopyranoside; LDAO, lauryldimethylamine-N-
oxide; MBP, maltose binding protein; NT, nucleoside transporters; OG, octyl
β-D-glucopyranoside.
MATERIALS AND METHODS
Reagents and Plasmids
We produced HRV-3C protease with an N-terminal octahistidine
tag, which had been ligated into a pET28 derivative vector.
The protease was purified by IMAC after expression in
E. coli (Postis, unpublished). The detergents dodecyl-β-D-
maltoside (DDM) and decyl-β-D-maltoside (DM) were from
GLYCON Biochemicals GmbH (Luckenwalde, Germany),
lauryldimethylamine-N-oxide (LDAO), and octaethylene glycol
monododecyl ether (C12E8) were from Anatrace (Maumee,
USA) and octyl β-D-glucopyranoside (OG) was from Affymetrix
Inc (Santa Clara, USA). Isopropyl β-D-1-thiogalactopyranoside
(IPTG) was from Melford Ltd. (Chelsworth, UK). The vectors
pL53 and pL55 employed in this study are as described in our
previous report (Ma et al., 2015), and the same strategy was used
to generate pL54.
Protein Expression
The optimal expression conditions of proteins with the different
vectors were obtained from expression optimizations following
protocols in (Baldwin, 2000). A single colony was transferred in
300 ml Luria Broth medium for incubation overnight at 37◦C.
The large scale expression of the target protein was conducted
in 30 l fermentor (Infors HT). The cells were grown in Terrific
Broth medium at 37◦C until an OD600 of 0.6 was reached.
The expression of the target of interest was induced by the
addition of 0.5 mM IPTG. The cells were harvested after 6 h by
centrifugation.
Membrane Preparation
Membrane preparation was performed as previously published
(Ma et al., 2015). Briefly, after being resuspended at 6 mg/ml
(wet cell weight) in phosphate-buffered saline (PBS), the cells
were disrupted at 30 kpsi using a TS series cell disruptor
(Constant Systems Ltd., UK). The cell debris were removed by
centrifugation at 14,000 g for 45 min. The membrane fraction
was pelleted by ultracentrifugation at 100,000 g for 2 h. The
membrane pellet was washed twice with PBS buffer. The
final membrane pellet was resuspended in PBS buffer to a
concentration of total membrane protein between 20 and 40
mg/ml and snap-frozen in liquid nitrogen.
Solubilisation Trials
Solubilisation trials were carried out using a final membrane
protein concentration of 5 mg/ml in solubilisation buffer
(Table 1) and 1% (w/v) of the tested detergents. Five different
detergents were tested: DDM, DM, LDAO, C12E8, and OG. The
resuspended samples were gently mixed for 2 h at 4◦C. The
suspensions were centrifuged at 100,000 g for 1 h. The protein
of interest in the collected supernatants was detected by western
blot (anti-histidine tag antibody) and its amount compared to the
total amount of NupC present before centrifugation.
Protein Purification
All experiments were performed at 4◦C unless stated otherwise.
The standard purification was described in Ma et al. (2015) and
the optimized purification was carried out as follow. Membrane
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TABLE 1 | Buffers.
Buffer Composition
1*PBS 10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM sodium chloride, 4 mM potassium chloride, pH 7.4
Solubilisation buffer 50 mM Tris pH 7.4, 150 mM sodium chloride, 5% (w/v) glycerol, 5 mM imidazole
Purification buffer 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 5 mM imidazole, 5% glycerol (w/v), and 1% DDM
Wash buffer 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 15 mM imidazole, 0.05% DDM, and 10% glycerol (w/v)
Cleavage buffer 50 mM potassium phosphate buffer pH 7.4, 150 mM sodium chloride, 5% glycerol (w/v), and 0.05% DDM
proteins (100 mg) were solubilised in purification buffer for 1
h. The non-solubilised material was removed by centrifugation
(100,000 g for 1 h). The supernatant was collected and incubated
with 4 ml HisPur
TM
Cobalt resin (Thermo Scientific
TM
) for 1
h on a roller mixer. The resin was then packed into a column
and washed with 10 column volumes (CV) of wash buffer.
The washed resin was then resuspended in 1 CV of cleavage
buffer and incubated for 2 h with the appropriate amount
of HRV-3C protease (molar ratio target protein to protease
1: 5). Afterwards, the flowthrough containing the protein of
interest was collected and the resin was washed with 1 CV of
cleavage buffer. Excess protease was removed from the protein
solution by incubating it for 15 min with 4 ml of Ni-NTA
resin slurry (Thermo ScientificTM) on a roller mixer. The cleaved
protein was collected by transferring the suspension to an
empty column and washing the resin with 1 CV of cleavage
buffer. The protein was concentrated with a 30 kDa cut-off
concentrator (Sartorius Stedim Biotech, 20 mL) for further
experiments.
RESULTS
Advantages of the Novel pL55 MBP Fusion
Vector
The expression of NupC is under the control of a strong promoter
(T7) in pL54 and a weak one (ptac) in pL53. On the other hand,
the linker between the MBP and HRV3C protease cleavage site is
shorter in pL54 than in pL53 (Figure 1). The stronger promoter
led to a higher level of expression (Figure 2A). Furthermore,
as shown in Figure 3, the longer linker present in the protein
expressed by pL53 led to better cleavage of the tag. Less HRV-
3C protease is required to completely cleave protein expressed in
pL53 than in pL54.
We therefore created a new MBP fusion vector, pL55,
which includes a T7 promoter, a periplasmic targeting sequence
(pelB), an octa histidine tag, MBP, and a human rhinovirus
3C protease cleavage site (HRV3C). The level of expression
of NupC in a pL55 context is almost equivalent to level
observed for pL54, and approximately double compared to
pL53 (Figure 2A). This suggests that constructs with a T7
promoter (pL54 and pL55) could yield much more target
membrane protein than constructs with a ptac promoter
(pL53).
The efficient solubilisation of NupC produced by the pL55
construct by 5 different detergents shows that changing the
length of the linkers or the strength of the promoter does not
FIGURE 1 | Description of the plasmids used in this study.
lead to the expression of the recombinant protein into inclusion
bodies (Figure 2B). The pL55 vector, with a strong promoter
and a long linker, thus combines the advantages of both pL53
and pL54 vectors. The expressed NupC was functional in all
three different vectors according to a transport assay (Ma et al.,
2015).
Additionally, we tested the cleavage efficiency of NupC
expressed in pL53, pL54, and pL55 in the presence of different
molar ratios of NupC:HRV3C after 16 h (Figure 3). The results
show that the cleavage efficiency of NupC in pL53 was clearly
higher than in pL54. The fusion NupC in pL55 can be cleaved
efficiently following the same molar ratio NupC:HRV of 5:1
obtained from the test in pL53, as they possess equivalent length
linker.
Optimization of Purification Using MBP
Fusion Protein
A crucial parameter in membrane protein purification is the
time required for their purification. The low stability of most
membrane proteins inevitably leads to decreased protein yields
due to denaturation, aggregation, and proteolysis during long
purification protocols.
Our previous purification protocols for NupC required
long binding times (usually overnight) of the resin with
solubilized membrane proteins for complete adsorption, in
order to maximize the final yield. In this new approach, we
decided to investigate how the amount of unbound NupC
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FIGURE 2 | Expression level and solubilisation level of NupC expression. (A) Comparison of the expression of NupC in pL53, pL54, pL55. Un, uninduced cell
culture; I, cell culture after induction; (B) Solubilization trial of NupC expressed in the pL55 vector using five different detergents.
FIGURE 3 | Cleavage efficiency of NupC in the presence of different molar ratios of NupC:HRV3C after 16 h of digestion. (A) pL53 construct, (B) pL54
construct, and (C) pL55 construct. 1, 1: 10 ratio; 2, 1: 5 ratio; 3, 1: 2 ratio; 4, 1: 1 ratio; 5, 2: 1 ratio; 6, 5: 1 ratio; C, control NupC without HRV-3C.
varied with incubation time. The Co-resin was incubated with
solubilized NupC for 12 h. Samples were taken at 1, 2, 3,
4, and 12 h, centrifuged, and the amount of unbound target
protein in the supernatant was determined via western blot
and compared to the total initial amount. We found that
more than 95% of the solubilized tagged protein was bound
to the resin within 2 h, suggesting that the binding time
could be significantly shortened from overnight to 2 h to
avoid loss of activity during the long purification process
(Figure 4A).
Conventional membrane protein production methods also
generally require a long time for cleaving the MBP fusion
protein off (overnight or even longer). To investigate how
quickly cleavage occurs, we added the protease to the column-
bound membrane protein (molar ratio NupC:HRV of 5:1)
and compared the cleaved to uncleaved protein ratio at
different incubation times by western blot (anti-histidine tag
antibody) (Figure 4B). The results indicate that about 90%
of the fusion protein was cleaved within 2 h, and that
a longer incubation time did not significantly increase the
cleavage yield. Therefore, the digestion time was reduced
from 16 to 2 h in the optimized method. To determine the
amount of protease required to achieve this, we examined the
cleavage efficiency using different amounts of protease against
recombinant NupC in the three different vectors (Figure 3). Our
findings show that a 5:1 molar ratio of NupC:HRV protease
was sufficient during the 16 h cleavage of NupC in the pL53
and pL55 vectors, which possess the same long linker. On the
contrary, cleavage of NupC in pL54 with a short linker proved
difficult, even using a large amount of protease (NupC:HRV
of 1:1).
The purity of the protein was subsequently evaluated. After
cleavage and concentration steps, the purified protein was
loaded onto SDS-PAGE and stained with Coomassie Blue.
Unexpectedly, three main bands were observed on the gel in
addition to the NupC monomer (Figure 5). All four bands
were identified as NupC by mass spectrometry analysis (data
not shown), consistent with the fact that NupC can form
higher oligomers and in particular trimers as seen in the 3D
structure (Johnson et al., 2012). This suggests that purified
NupC retains its native trimeric structure even in SDS-PAGE.
Band 1 (less than 37 kDa) is presumably the NupC monomer.
Bands 2 and 3 correspond to a dimer and trimer respectively,
while band 4 (above 100 kDa) is some higher-order oligomeric
structure.
This purification strategy has broad range applications
for other membrane proteins. This is illustrated by the
successful purification of the nucleoside transporter
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FIGURE 4 | Time course of NupC (pL55) binding to the resin and cleavage of the resin (molar ratio NupC:HRV3C of 5:1). (A) Binding rate of NupC, the
presence of the protein in the supernatant is detected by western blot using an antibody against the His tag. (B) Rate of cleavage of the protein from the cobalt resin.
The quantity of uncleaved protein is measured by western blot using an antibody against the His tag. M, incubation of resin mixture after short spin (Cobalt resin and
1st dialysis buffer, plus HRV-3C); SN, supernatant of mixture after short spin (Cobalt resin and 1st dialysis buffer, plus HRV-3C); C, control fusion NupC.
FIGURE 5 | SDS-PAGE of the purified NupC in DDM performed via the
optimized procedure. S, solubilized fraction after ultracentrifugation; FT,
Flow through of cobalt resin; W1, washing step 1; W2, washing step 2; HRV,
purified human rhinovirus 3C-protease; C1, fractions after cleavage; C2, flow
through after incubation with Nickel resin to remove residual protease; MS,
concentrated protein sample with labeled bands investigated via mass
spectrometry. Band 1: expected molecular mass of NupC monomer.
from Anoxybacillus flavithermus, Bacillus halodurans,
and Rhodothermus marinus using this optimized strategy
(SI-Figure 1).
DISCUSSION
For a long time, the low yield of membrane proteins has
presented a major obstacle for their structural and functional
studies, especially for NTs. Many attempts have been made to
overcome this problem using various expression strains, vectors
and media for membrane proteins (Winstone et al., 2002; Drew
et al., 2006; Öberg et al., 2011; Schlegel et al., 2012). The MBP
protein, which was reported to increase the stability and solubility
of membrane proteins (Gruswitz et al., 2005; Raran-Kurussi et al.,
2015), was introduced into our nucleoside transporter expression
vectors. Meanwhile, it has been reported that different promoters
could change the expression level of target proteins, and a strong
promoter, such as the T7 promoter in pL54, can facilitate the
overexpression of the target protein (Berg et al., 2012; Phan
et al., 2012; Hensel et al., 2013; Binder et al., 2014). Through
combining a strong promoter for enhanced protein expression
with MBP enhancing the protein stability as fusion partner we
were able to construct a new expression vector (pL55), which
resulted in significantly higher protein yields than our earlier
vectors.
A limiting step in the purification of MBP fusion proteins
has often been the rate of proteolytic cleavage of the MBP
from the target proteins. It was reported that the incomplete
digestion resulted from the presence of certain detergents
during purification (Mohanty et al., 2003). Hu and colleagues
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FIGURE 6 | Technical routes of the two purification protocols. The conventional method is shown in italics, and the optimized one in bold.
speculated that detergent solubilisation of the hydrophobic
cleft on the surface of MBP may form a binding site for the
hydrophobic domain of the target membrane protein, which
potentially results in a stable non-covalent complex following
protein cleavage (Hu et al., 2011). In other words, the activity
of the proteolytic enzyme can be dramatically reduced in the
detergents used to solubilize membrane proteins (Vergis and
Wiener, 2011). However, our results suggest that the rate of
digestion is also dependent on the length of the linker between
MBP and the target protein. We observed that digestion was
more efficient when linkers were longer (pL55 and pL53,
both 19 amino acids), as opposed to a shorter linker (pL54,
3 amino acids) (Figure 3). This is presumably because the
cleavage site is more exposed and therefore more accessible to
proteolytic enzymes when long linkers are employed. Indeed,
smaller amounts of protease were needed to perform efficient
digestion on the new His-MBP-NupC fusion expressed from
our new vector, pL55, compared to pL54, a similar construct
with a shorter linker. This means that the target protein can
be purified much faster using the new vectors and methods
(Figure 6): the time taken after ultracentrifugation is reduced
from 37 to 6.5 h—almost a factor of six. Additionally,
compared to the traditional purification protocol, the new
method significantly reduces the consumption of reagents and
lab consumables.
Furthermore, our new optimized method is particularly
interesting for crystallization purposes. In traditional purification
experiments, large volumes are used to elute the target protein
efficiently. This implies that the purified protein is very
diluted and a concentration step is required before downstream
application. This in turn concentrates the detergent and has
an impact on crystallization efficiency and crystal quality
(Prince and Jia, 2013). Our optimized protocol describes how
adding the protease directly onto the column-bound target
protein reduces the volume of elution, hence yielding a more
concentrated protein. Further protein concentration steps are
therefore minimized, avoiding unnecessary collateral increase
in detergent concentration, which is an important asset in
crystallographic studies. Our new optimized strategy presents
strong advantages over classical approaches in terms of time, cost,
and quality ofmembrane protein purification for crystallographic
studies.
AUTHOR CONTRIBUTIONS
AG, ZH, VP, YW, MB designed the experiments. ZH, VP, AL,
MT, DS performed the experiments. The data were analyzed by
ZH, MT, VP, AL, AG. The paper was written by ZH, MT, VP, YW,
MB, and AG.
FUNDING
The authors are grateful to the financial support from the
National key fundamental research project (973 project,
2014CB560709, to MB), National Science Foundation
of China (31570128 to MB and 31270545 to YW), and
the Royal Society Wolfson Research Merit Award, the
Wellcome Trust (ref. 019322/7/10/Z), BBSRC (BB/M021610/1)
and the Academy of Finland (1286429) (all to AG). ZH
Frontiers in Molecular Biosciences | www.frontiersin.org 6 June 2016 | Volume 3 | Article 23
Hao et al. NTs Novel and Fast Purification
was funded by an award from the China Scholarship
Council.
ACKNOWLEDGMENTS
As colleagues and friends of Steve Baldwin, we dedicate this paper
to him in memoriam.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmolb.
2016.00023
SI-Figure 1 | SDS-PAGE of the purified CNT from Anoxybacillus
flavithermus (Af), Bacillus halodurans (Bh), Rhodothermus marinus (Rm)
in DDM performed via the optimized procedure.
REFERENCES
Alexandrov, A., Dutta, K., and Pascal, S. M. (2001). MBP fusion protein with a
viral protease cleavage site: one-step cleavage/purification of insoluble proteins.
Biotechniques 30, 1194–1198. doi: 10.1017/S1355838202024019
Almén, M. S., Nordström, K. J., Fredriksson, R., and Schiöth, H. B. (2009).
Mapping the human membrane proteome: a majority of the human membrane
proteins can be classified according to function and evolutionary origin. BMC
Biol 7:50. doi: 10.1186/1741-7007-7-50
Andreeva, A., Howorth, D., Chothia, C., Kulesha, E., and Murzin, A. G. (2014).
SCOP2 prototype: a new approach to protein structure mining. Nucleic Acids
Res. 42, D310–D314. doi: 10.1093/nar/gkt1242
Anson, L. (2009). Membrane protein biophysics. Nature 459, 343. doi:
10.1038/459343a
Baldwin, S. A. (2000).Membrane Transport: A Practical Approach. New York, NY:
Oxford University Press.
Bayley, H. (2009). Membrane-protein structure: piercing insights. Nature 459,
651–652. doi: 10.1038/459651a
Berg, L., Kucharova, V., Bakke, I., Valla, S., and Brautaset, T. (2012). Exploring the
5’-UTR DNA region as a target for optimizing recombinant gene expression
from the strong and inducible Pm promoter in Escherichia coli. J. Biotechnol.
158, 224–230. doi: 10.1016/j.jbiotec.2011.07.012
Binder, D., Grünberger, A., Loeschcke, A., Probst, C., Bier, C., Pietruszka, J., et al.
(2014). Light-responsive control of bacterial gene expression: precise triggering
of the lac promoter activity using photocaged IPTG. Integr. Biol. (Camb.) 6,
755–765. doi: 10.1039/c4ib00027g
Bowie, J. U. (2005). Solving the membrane protein folding problem. Nature 438,
581–589. doi: 10.1038/nature04395
Carrier, E. J., Auchampach, J. A., and Hillard, C. J. (2006). Inhibition of
an equilibrative nucleoside transporter by cannabidiol: a mechanism of
cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 103, 7895–7900.
doi: 10.1073/pnas.0511232103
Dälken, B., Jabulowsky, R. A., Oberoi, P., Benhar, I., and Wels, W. S. (2010).
Maltose-binding protein enhances secretion of recombinant human granzyme
B accompanied by in vivo processing of a precursor MBP fusion protein. PLoS
ONE 5:e14404. doi: 10.1371/journal.pone.0014404
Drew, D., Lerch, M., Kunji, E., Slotboom, D. J., and De Gier, J. W. (2006).
Optimization of membrane protein overexpression and purification using GFP
fusions. Nat. Methods 3, 303–313. doi: 10.1038/nmeth0406-303
Drew, D., Newstead, S., Sonoda, Y., Kim, H., Von Heijne, G., and Iwata, S. (2008).
GFP-based optimization scheme for the overexpression and purification of
eukaryotic membrane proteins in Saccharomyces cerevisiae. Nat. Protoc. 3,
784–798. doi: 10.1038/nprot.2008.44
Drew, D., Slotboom, D. J., Friso, G., Reda, T., Genevaux, P., Rapp, M., et al. (2005).
A scalable, GFP-based pipeline for membrane protein overexpression screening
and purification. Protein Sci. 14, 2011–2017. doi: 10.1110/ps.051466205
Gosch, C., Nagesh, K. M., Thill, J., Miosic, S., Plaschil, S., Milosevic, M., et al.
(2014). Isolation of dihydroflavonol 4-reductase cDNA clones from Angelonia
x angustifolia and heterologous expression as GST fusion protein in Escherichia
coli. PLoS ONE 9:e107755. doi: 10.1371/journal.pone.0107755
Gruswitz, F., Frishman, M., Goldstein, B. M., andWedekind, J. E. (2005). Coupling
of MBP fusion protein cleavage with sparse matrix crystallization screens
to overcome problematic protein solubility. Biotechniques 39, 478, 480. doi:
10.2144/000112033
Heijbel, A., Carlsson, M., and Karlsson, A. (2009). Purification of MBP- and
Strep-tag II proteins. Faseb J. 23.
Hensel, M., Borgeaud, S., and Blokesch, M. (2013). Overexpression of the tcp
gene cluster using the T7 RNA polymerase/promoter system and natural
transformation-mediated genetic engineering of Vibrio cholerae. PLoS ONE
8:e53952. doi: 10.1371/journal.pone.0053952
Hsu, C. L., Lin, W., Seshasayee, D., Chen, Y. H., Ding, X., Lin, Z., et al. (2012).
Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function
and macrophage homeostasis. Science 335, 89–92. doi: 10.1126/science.12
13682
Hu, J., Qin, H., Gao, F. P., and Cross, T. A. (2011). A systematic
assessment of mature MBP in membrane protein production: overexpression,
membrane targeting and purification. Protein Expr. Purif. 80, 34–40. doi:
10.1016/j.pep.2011.06.001
Johnson, Z. L., Cheong, C. G., and Lee, S. Y. (2012). Crystal structure of a
concentrative nucleoside transporter from Vibrio cholerae at 2.4 A. Nature 483,
489–493. doi: 10.1038/nature10882
Krogh, A., Larsson, B., Von Heijne, G., and Sonnhammer, E. L. (2001). Predicting
transmembrane protein topology with a hidden Markov model: application to
complete genomes. J. Mol. Biol. 305, 567–580. doi: 10.1006/jmbi.2000.4315
Lacapere, J. J., Pebay-Peyroula, E., Neumann, J. M., and Etchebest, C. (2007).
Determining membrane protein structures: still a challenge! Trends Biochem.
Sci. 32, 259–270. doi: 10.1016/j.tibs.2007.04.001
Lorenzo, H. K., Farber, D., Germain, V., Acuto, O., and Alzari, P. M. (1997). The
MBP fusion protein restores the activity of the first phosphatase domain of
CD45. FEBS Lett. 411, 231–235.
Ma, C., Hao, Z., Huysmans, G., Lesiuk, A., Bullough, P., Wang, Y., et al.
(2015). A versatile strategy for production of membrane proteins with diverse
topologies: application to investigation of bacterial homologues of human
divalent metal ion and nucleoside transporters. PLoS ONE 10:e0143010. doi:
10.1371/journal.pone.0143010
Midgett, C. R., and Madden, D. R. (2007). Breaking the bottleneck: eukaryotic
membrane protein expression for high-resolution structural studies. J. Struct.
Biol. 160, 265–274. doi: 10.1016/j.jsb.2007.07.001
Mohanty, A. K., Simmons, C. R., and Wiener, M. C. (2003). Inhibition of tobacco
etch virus protease activity by detergents. Protein Expr. Purif. 27, 109–114. doi:
10.1016/S1046-5928(02)00589-2
Nguyen, M. T., Koo, B. K., Thi Vu, T. T., Song, J. A., Chong, S. H., Jeong, B., et al.
(2014). Prokaryotic soluble overexpression and purification of bioactive human
growth hormone by fusion to thioredoxin, maltose binding protein, and protein
disulfide isomerase. PLoS ONE 9:e89038. doi: 10.1371/journal.pone.0089038
Öberg, F., Sjöhamn, J., Conner, M. T., Bill, R. M., and Hedfalk, K. (2011).
Improving recombinant eukaryotic membrane protein yields in Pichia pastoris:
the importance of codon optimization and clone selection. Mol. Membr. Biol.
28, 398–411. doi: 10.3109/09687688.2011.602219
Phan, T. T., Nguyen, H. D., and Schumann, W. (2012). Development of a strong
intracellular expression system for Bacillus subtilis by optimizing promoter
elements. J. Biotechnol. 157, 167–172. doi: 10.1016/j.jbiotec.2011.10.006
Prince, C. C., and Jia, Z. (2013). Detergent quantification in membrane protein
samples and its application to crystallization experiments. Amino Acids 45,
1293–1302. doi: 10.1007/s00726-013-1600-3
Raran-Kurussi, S., Keefe, K., and Waugh, D. S. (2015). Positional effects of fusion
partners on the yield and solubility of MBP fusion proteins. Protein Expr. Purif.
110, 159–164. doi: 10.1016/j.pep.2015.03.004
Frontiers in Molecular Biosciences | www.frontiersin.org 7 June 2016 | Volume 3 | Article 23
Hao et al. NTs Novel and Fast Purification
Rehan, S., and Jaakola, V. P. (2015). Expression, purification and functional
characterization of human equilibrative nucleoside transporter subtype-1
(hENT1) protein from Sf9 insect cells. Protein Expr. Purif. 114, 99–107. doi:
10.1016/j.pep.2015.07.003
Sammons, J. D., and Gross, A. K. (2013). Biochemical analysis of a rhodopsin
photoactivatable GFP fusion as a model of G-protein coupled receptor
transport. Vision Res. 93, 43–48. doi: 10.1016/j.visres.2013.10.008
Satoh, K., Oti, T., Katoh, A., Ueta, Y., Morris, J. F., Sakamoto, T., et al.
(2015). In vivo processing and release into the circulation of GFP
fusion protein in arginine vasopressin enhanced GFP transgenic rats:
response to osmotic stimulation. FEBS J. 282, 2488–2499. doi: 10.1111/febs.
13291
Schlegel, S., Löfblom, J., Lee, C., Hjelm, A., Klepsch, M., Strous, M., et al. (2012).
Optimizing membrane protein overexpression in the Escherichia coli strain
Lemo21(DE3). J. Mol. Biol. 423, 648–659. doi: 10.1016/j.jmb.2012.07.019
Valdés, R., Elferich, J., Shinde, U., and Landfear, S. M. (2014). Identification of
the intracellular gate for a member of the equilibrative nucleoside transporter
(ENT) family. J. Biol. Chem. 289, 8799–8809. doi: 10.1074/jbc.M113.
546960
Vergis, J. M., and Wiener, M. C. (2011). The variable detergent sensitivity of
proteases that are utilized for recombinant protein affinity tag removal. Protein
Expr. Purif. 78, 139–142. doi: 10.1016/j.pep.2011.04.011
Von Heijne, G. (2006). Membrane-protein topology. Nat. Rev. Mol. Cell Biol. 7,
909–918. doi: 10.1038/nrm2063
Winstone, T. L., Duncalf, K. A., and Turner, R. J. (2002). Optimization
of expression and the purification by organic extraction of the integral
membrane protein EmrE. Protein Expr. Purif. 26, 111–121. doi: 10.1016/S1046-
5928(02)00525-9
Xu, Y., Chen, B., He, Q. H., Qiu, Y. L., Liu, X., He, Z. Y., et al. (2014).
New approach for development of sensitive and environmentally friendly
immunoassay for mycotoxin fumonisin B(1) based on using peptide-MBP
fusion protein as substitute for coating antigen. Anal. Chem. 86, 8433–8440.
doi: 10.1021/ac502037w
Young, J. D., Yao, S. Y., Baldwin, J. M., Cass, C. E., and Baldwin, S. A. (2013). The
human concentrative and equilibrative nucleoside transporter families, SLC28
and SLC29.Mol. Aspects Med. 34, 529–547. doi: 10.1016/j.mam.2012.05.007
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Hao, Thomsen, Postis, Lesiuk, Sharples, Wang, Bartlam and
Goldman. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Molecular Biosciences | www.frontiersin.org 8 June 2016 | Volume 3 | Article 23
